Are We Overtreating DCIS?

Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Dostarlimab/chemotherapy elicited a 31% decrease in the risk of death compared with placebo/chemotherapy in locally advanced/recurrent endometrial cancer.